The interaction between prognostic and pharmacodynamic biomarkers.
Affiliation
Department of Mathematics and Statistics, Fylde College, Lancaster University, Lancaster, UK.Issue Date
2013-10-01
Metadata
Show full item recordAbstract
Interactions between prognostic and pharmacodynamic (PD) biomarkers have received little attention.Citation
The interaction between prognostic and pharmacodynamic biomarkers. 2013, 109 (7):1782-5 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2013.527PubMed ID
24002599Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2013.527
Scopus Count
Collections
Related articles
- Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.
- Authors: Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG
- Issue date: 2012 Oct 23
- Percentage Change in Plasma Cytokeratin 18 Is Associated with Clinical Outcomes in Patients Receiving Pemetrexed and Carboplatin for the Adenocarcinoma Subtype of NSCLC.
- Authors: Strimpakos AS, Banerji U, Thavasu P, Tsilimagou A, Psyrri A, Syrigos KN
- Issue date: 2015
- Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.
- Authors: de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, Gietema JA
- Issue date: 2008 Oct
- Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma.
- Authors: Li XM, Huang WG, Yi H, Cheng AL, Xiao ZQ
- Issue date: 2009 Dec
- Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
- Authors: Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S
- Issue date: 2016 Jul 1